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Abstract Hyperpolarized 13C magnetic resonance is a powerful tool for the study
of cardiac metabolism. In this work, we have implemented protocols for the real-
time hyperpolarized 13C investigation of Langendorff-perfused rat hearts using both
non-selective non-localized spectroscopy and fast spectroscopic imaging. Following
[1-13C] pyruvate infusion, we observed both catabolic and anaplerotic metabolic
processes resulting in a number of metabolites, including bicarbonate, carbon
dioxide, lactate, alanine and aspartate. Employing fast spectroscopic imaging, we
were able to observe regional variations in pyruvate perfusion as well as in lactate
and bicarbonate production.
1 Introduction
The Langendorff-perfused heart is an ex vivo model that allows the investigation of
cardiac function and metabolic processes in a strictly controlled environment [1].
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Various physiological and pathophysiological conditions of the heart can be
reproduced using this model by direct control of its environment, substrate supply or
energy requirements. Moreover, it provides the possibility to investigate the effect
of endogenous and exogenous substances on cardiac metabolism, making it a key
pharmacological research tool. In combination with appropriate non invasive
methods like magnetic resonance spectroscopy (MRS) and imaging, it is a powerful
preclinical approach for basic research, allowing the assessment of the effects of
various cardiac interventions, such as small molecule inhibitors [2], up- and down-
regulation of signal transduction pathways [3] and response to ischemia–reperfusion
injury [4].
Magnetic resonance spectroscopy can give insight into the role of cardiac
metabolism under various conditions. In the perfused heart 31P MRS is traditionally
employed to measure intracellular concentrations of adenosine triphosphate (ATP)
and phosphocreatine (PCr) [5–7]. 1H MRS has been previously used to measure
total creatine content [8] and triglyceride accumulation in ischemic myocardium [9],
whereas 13C MRS can be used to measure glucose oxidation [10]. Both 31P and 1H
MRS have been translated to clinical application, for the quantification of
pathophysiological changes in myocardial high-energy phosphate metabolism,
creatine and triglyceride concentrations in patients, which can be affected by aortic
stenosis [11], cardiomyopathy [12], ischemia [13] or diabetes [14, 15]. However,
due to its relatively low sensitivity, the range of metabolites which are quantifiable
by MRS for dynamic in vivo investigation are limited.
The recently introduced method of dissolution dynamic nuclear polarization (DNP)
provides a possibility to enhance the MRS signal from nuclei by the order of tens of
thousands [16], to facilitate the measurement of the kinetics of metabolic processes in
healthy or diseased tissue previously inaccessible to nuclear magnetic resonance
(NMR). Hyperpolarized [1-13C] pyruvate infusion has previously been shown to allow
the measurement of pyruvate dehydrogenase activity (PDH) ex vivo in the perfused rat
heart [17, 18] and in vivo under conditions such as diabetes and hypertrophy [19, 20].
Hyperpolarized [2-13C] pyruvate can be used to assess the Krebs cycle showing
significant decreases of TCA cycle intermediates, such as 13C citrate and 13C glutamate,
in response to ischemia [21]. Moreover, PDH and TCA cycle activity can be assessed
simultaneously through the use of hyperpolarized [1,2-13C2] pyruvate [22]. Fatty acid
metabolism has also been probed through the buffering of hyperpolarized acetate with
acetyl carnitine in response to recovery from periods of ischemia [23] or through the
addition of water soluble fatty acids such as octanoate [17].
While information from non-selective MRS is sufficient for estimating metabolic
changes and pathologies with global effects, spatially resolved spectroscopy is
needed to study local effects in the heart. Magnetic resonance spectroscopic
imaging (MRSI) potentially provides the capacity to study local effects in the heart,
allowing the characterization of heterogeneous metabolic changes and pathologies
such as found in ischemic heart disease [24–26].
MRSI of hyperpolarized material poses additional challenges compared with that
of more traditional thermally polarized 1H MRSI. The rapidly decaying nature of
hyperpolarization to thermal equilibrium and the metabolic conversion by enzymatic
reactions require fast spectroscopic imaging techniques. The hyperpolarized
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magnetization needs to be traded between individual images and the number of
dynamics in the imaging series. To preserve the magnetization for all dynamics, a low
number of signal excitations in combination with small flip angles are desired. At the
same time sufficient signal-to-noise ratio (SNR) needs to be assured. Various
approaches have been proposed to address these challenges [27, 28] and in vivo
applications of these techniques have been demonstrated in pig hearts [29].
In the present work an experimental set up for hyperpolarized 13C-MR
spectroscopy and imaging was implemented in perfused rat hearts. In our
experiments we detected the metabolic conversion from pyruvate to lactate,
alanine, HCO3
- and CO2, as well as a previously unobserved conversion from
pyruvate to aspartate attributed to anaplerotic metabolism via the action of pyruvate
carboxylase. To address the need for spatial resolution, fast spectroscopic imaging
was implemented using echo planar spectroscopic imaging (EPSI) [30] allowing
dynamic visualization of the spatial distribution of bicarbonate and lactate
metabolites. Regional heterogeneity of these metabolite signals was observed.
2 Experimental Methods
2.1 Isolated Heart Perfusion
All animal experiments were carried out in accordance with local regulations [Home
Office Guidance on the Operation of Animals (Scientific Procedures) Act 1986,
HMSO (London)]. Male Wistar rats (250–300 g) underwent terminal anesthesia by
intraperitoneal injection of 0.4 mL of sodium pentobarbitone. After assuring the
absence of pedal pain withdrawal reflexes, 0.2 mL of heparin was injected into the
femoral vein. The heart was harvested and placed in cold Krebs-Henseleit buffer to
temporarily arrest it and minimize ischemic injury [31]. The isolated heart was
cannulated to re-establish vascular perfusion [32] employing a plastic cannula
(ø = 3 mm) inserted into the aorta and perfused with modified Krebs-Henseleit
buffer (NaCl 118 mM, NaHCO3 25 mM, MgSO4 1.2 mM, KCl 5.9 mM, Na2EDTA
0.6 mM, glucose 11.1 mM, CaCl2 2.5 mM, pH * 7.4, continuously oxygenated by
bubbling 95 % O2, 5 % CO2) at a constant flow of 14 ml/min to achieve a constant
pressure at the coronary arteries of 76 mmHg (monitored by an in-line pressure
transducer). Temperature was maintained at 37 C using a thermostatically
controlled water-jacketed system.
2.2 DNP
14 ll of [1-13C] pyruvic acid containing 15 mM trityl radical and 1 mM
Gadolinium (Gd) (Dotarem) was hyperpolarized in a HyperSense (Oxford
Instruments) DNP at 3.35 T and 1.4 K for *1 h. Dissolution was performed
employing 4 ml of 40 mM TRIS buffer. Pyruvic acid was neutralized by addition of
a number of moles of NaOH equal to that of the pyruvate sample to the collection
vessel. The solution state hyperpolarization was measured in a separate experiment
to be of the order P & 22 % (extrapolated back to the instant of the dissolution),
Developing Hyperpolarized 13C Spectroscopy 277
123
corresponding to an enhancement factor of &27,000 measured with respect to the
thermal signal of the same sample acquired under Ernst angle conditions after signal
decay. Immediately following dissolution, 3 ml of hyperpolarized [1-13C] pyruvate
(50 mM) was injected into the perfusion line at constant flow (1 ml/min) from an
automated injector, resulting in a final concentration of hyperpolarized solution of
*3.3 mM pyruvate in the perfusion buffer at the arrival to the heart.
2.3 MR Spectroscopy and Imaging
All experiments were carried out on a vertical wide bore Bruker 9.4T Avance III
spectrometer with the bore maintained at 37 C. The perfused heart was inserted in
a glass tube (ø = 15 mm, with a silicone bung) filled with Krebs-Henseleit buffer.
Coronary perfusate was aspirated from the top by a gravity-fed siphon.
For non-selective spectroscopic measurements (n = 5), the tube containing the
perfused heart was placed within the isocenter of a custom-built 23Na/13C saddle
coil (ø = 15 mm) and inserted into the spectrometer. Shimming was carried out
using the 23Na signal (FWHM 13 Hz) and then re-tuned to 13C. Acquisition of the
NMR data commenced at the end of the dissolution and a time-series of 13C-MR
spectra (n = 128) was acquired using a single acquisition per spectrum, a small flip
angle pulse (h = 10) and a time resolution of 2 s. 13C-MRS data were processed
and analyzed using TopSpin (Bruker). All spectra were baseline corrected and
integrals of each peak extracted as a function of time. To estimate variability
between measurements, we summed the entire time-series of spectra for each heart,
estimating the total area under the metabolite peak, normalized to the total pyruvate
area, as well as the ratio HCO3
-/CO2 and the corresponding pH. In the imaging
experiments (n = 2) a dual-tuned 1H/13C birdcage coil with 20 mm inner diameter
was employed. Shimming was performed on the water signal using the 1H channel
of the coil (FWHM 35 Hz). Standard 1H cine images were acquired in short axis
(Fig. 1a) and four-chamber view (Fig. 1b) for planning purposes using a self-gated
gradient echo sequence [33] with the following parameters: TE: 2.9 ms, TR: 8 ms,
acquisition matrix: 128 9 128, field of view: 32 mm 9 32 mm, spatial resolution:
250 lm 9 250 lm, slice thickness: 5 mm, flip angle: 20, 10 cardiac frames.
(a)
LV
RV
LVRV
(b)
Fig. 1 a Time frame from a short axis 1H cine image acquired as reference for the 13C images. The left
ventricle can be seen in the middle of the image. The right ventricle can be seen on the top left. The white
dots outside the heart are incoming (bottom) and outgoing (top) perfusion line. b Four chamber view of
the isolated perfused heart from a 1H cine scan. The left ventricle can be seen on the right and the right
ventricle on the left. The closed aortic valve is visible as a bright spot at the top of the left ventricle
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Hyperpolarized 13C spectroscopic images were acquired using an echo planar
spectroscopic imaging (EPSI) sequence as shown in Fig. 2. The acquisition
parameters were as follows: TE: 1.315 ms, TR: 89 ms, time between dynamic
images: 5 s, acquisition matrix: 16 9 16, field of view: 32 mm 9 32 mm, flip
angle: &20, spatial resolution: 2 mm 9 2 mm, slice thickness: 5 mm, spectral
bandwidth during acquisition: 6,250 Hz, spectral resolution 12.2 Hz. For each
experiment 64 images were acquired in a total time of 320 s starting with the
dissolution of the sample. MRSI data were reconstructed using Matlab (Mathworks
Inc., Natick, MA). To avoid spectral N/2 ghosts, even and odd echoes of the echo
planar readout were combined after linear phase correction of the even echoes,
resulting in a spectral bandwidth of 3,125 Hz. For spatial visualization of the
distributions of pyruvate, lactate and bicarbonate, peak integrals were estimated on a
pixel by pixel basis and overlaid as color-coded 13C metabolite images to the 1H
reference images, interpolated to the same matrix size as the cine images. The color
scales are normalized independently to the maximum intensity for each metabolite.
Spectra were averaged within regions of interest for a given time frame and
phased using the pyruvate signal. The spectra reveal a linear phase due to the echo
time of 1.315 ms. This linear phase is taken into account by analyzing the data in
the time domain using the AMARES function of the jMRUI software package [34,
35]. The resonances of pyruvate at 173 ppm, pyruvate hydrate at 181 ppm, lactate at
185 ppm and bicarbonate at 162 ppm in the individual time frames were fitted
assuming Gaussian line profiles. For interpolation and display of the data signal
time curves of pyruvate, lactate and bicarbonate estimated with AMARES were
fitted using a bi-exponential function according to
SðtÞ ¼ a  ebt  ð1  ectÞ;
where S is the observed signal and a, b, c are free fitting parameters.
3 Results
A representative summed 13C spectrum is shown in Fig. 3a, obtained by summing
the entire hyperpolarized 13C time-series acquired after injection of [1-13C]
RF
Read
Phase
Slice
TE
Fig. 2 Schematic diagram of the echo planar spectroscopic imaging (EPSI) sequence. Slice selective
excitation is followed by phase encoding. The signal is acquired during an alternating gradient train
Developing Hyperpolarized 13C Spectroscopy 279
123
pyruvate. The spectrum shows a range of different metabolites that can be detected
including signals arising from pyruvate C1, natural abundance pyruvate C2 and
pyruvate hydrate and the metabolites that are produced by enzymatic conversion
corresponding to lactate C1, alanine C1, HCO3
-, CO2, aspartate C1 and aspartate
C4 as well as some other minor metabolites not yet assigned as seen in the figure
detail (top right). These minor peaks were not observed in the pyruvate preparation.
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Fig. 3 a Example hyperpolarized spectrum obtained by summing the entire time-series (128 spectra)
acquired as described in the ‘‘Experimental methods’’. Peaks correspond to pyruvate C1, natural
abundance pyruvate C2 and pyruvate hydrate and the metabolites that are produced corresponding to
lactate C1, alanine C1, HCO3
-, CO2, aspartate C1 and aspartate C4 as well as some other minor
metabolites not yet assigned as seen in the figure detail (top right). The peak * is a noise spike from the
coil. b Time series of 13C-MR spectra of hyperpolarized pyruvate C1 and its downstream metabolites
shown in a
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Figure 3b shows the temporal variation of each of these observed metabolite peaks
displayed as a function of time.
Figure 4a presents the mean and standard deviation for the total area under each
metabolite curve from the non-localized spectroscopic experiments (n = 5),
corresponding to the peak integrals of lactate C1, aspartate C4, alanine C1,
aspartate C1, HCO3
- and CO2, normalized to the total pyruvate signal. Figure 4b
shows the mean and standard deviations of the HCO3
-/CO2 ratio and corresponding
pH calculated using the Henderson–Hasselbalch equation. The latter is consistent
with the intracellular physiological pH in the heart measured previously [36].
Time series of images for pyruvate, lactate and bicarbonate from two individual
experiments are shown in Fig. 5a and b overlaid onto a time frame of a 1H cine
image in short axis view (Fig. 1a). The temporal interval between the dynamic
images is 5 s. The time frame t = 0 s was chosen to be the last time frame without
13C signal before the appearance of the hyperpolarized signal. Starting with
injection of hyperpolarized solution into the perfusion line, the signal of pyruvate is
visible in the inlet line indicated by the arrow in the pyruvate image in time frame
t = 5 s (top of Fig. 5a). Signal in the outflow tube can be found in time frame
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Fig. 4 a Mean and standard deviations (n = 5) of the total area under the curve formed by the peak
integrals of lactate C1, aspartate C4, alanine C1, aspartate C1, HCO3
- and CO2 normalized to the total
pyruvate signal. b Means and standard deviations (n = 5) of the HCO3
-/CO2 ratio and calculated pH
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t=5s
t=10s
t=15s
t=20s
t=25s
t=30s
pyruvate lactate bicarbonate
pyruvate
1
2
(a)
(c)
pyruvate lactate bicarbonate
pyruvate lactate bicarbonatelactate bicarbonate
Experiment 1 Experiment 2(b)
(d)
Fig. 5 a, b Time series of 13C images from a slice in short axis view of the myocardium overlaid on the
1H reference image (Fig. 1a). a and b show two different hearts. Images of pyruvate, lactate and
bicarbonate signals are shown in the 1st, 2nd and 3rd columns, respectively. The temporal resolution
between the images is 5 s, where time t = 0 s is defined to be the last image without 13C signal before
appearance of hyperpolarized [1-13C] pyruvate. The arrow in time frame t = 5 s in a indicates the
incoming perfusion line, the arrow in time frame t = 30 s in a indicates the outgoing tubing. c and
d Mean images of time frames t = 10 s to t = 20 s from the image series in a and b. The images show a
clear heterogeneous distribution of lactate and bicarbonate signals in experiment 1 (a and c). In
experiment 2 the distribution of lactate and bicarbonate is much more homogeneous b and d. The region
of high lactate and bicarbonate production in experiment 1 is indicated by arrow 1 and 2 respectively
282 K. Weiss et al.
123
t = 30 s, indicated by the arrow (bottom of Fig. 5a). The metabolic products lactate
and bicarbonate are visible in the myocardium from time frame t = 10 s. To further
increase the SNR of the images the mean of the time points t = 5 s to t = 20 s is
shown in Fig. 5c and d. It is apparent that in experiment 1 (Fig. 5a, c) the
distributions of pyruvate perfusion and the production of lactate and bicarbonate are
not homogeneous over the whole myocardium. In comparison, experiment 2
(Fig. 5b, d) shows a much more homogeneous distribution of the metabolic products
lactate and bicarbonate. The regions indicated by the arrows 1 and 2 in the lactate
and bicarbonate images of experiment 1 (Fig. 5c) reveal enhanced production of
lactate and bicarbonate, respectively, representing different metabolic processes
taking place in these regions. Time courses of pyruvate, lactate and bicarbonate
signal amplitudes estimated with AMARES from the two regions of interest in
experiment 1 and from the whole myocardium in experiment 2 are shown in
Fig. 6a–c. Fitted spectra of the regions of high lactate production and high
bicarbonate production of experiment 1 and the whole myocardium of experiment 2
are shown in Fig. 6d–f, together with fit residuals. Differences in the lactate
resonance at 185 ppm and the bicarbonate resonance at 162 ppm between the two
regions in experiment 1 and in experiment 2 are visible. Figure 6g–i shows a
stacked plot of the absolute spectra estimated with AMARES from the two regions
of interest indicated in Fig. 5b. Overall the signals from spectroscopic imaging are
clearly limited by SNR as can be seen in the images in Fig. 5 and the fitting
residuals in Fig. 6d–f. Furthermore, the temporal resolution is lower compared with
non-selective spectroscopy. However, the time courses of the signals are compa-
rable between the two techniques.
4 Discussion
A schematic diagram of the metabolic pathways we observed is shown in Fig. 7. We
observe conversion of hyperpolarized [1-13C] pyruvate to lactate catalyzed by
lactate dehydrogenase (LDH), to alanine catalyzed by alanine transaminase (ALT),
to bicarbonate catalyzed by PDH and interconversion of bicarbonate and CO2
catalyzed by carbonic anhydrase (CA). We also observe the conversion of
hyperpolarized [1-13C] pyruvate to aspartate C1 and C4 by transamination via
oxaloacetate. This is attributed to anaplerotic metabolism via the action of pyruvate
carboxylase (PC). The C1 label appears from direct conversion of pyruvate via
oxaloacetate. It has been suggested that the C4 signal in aspartate arises from TCA
cycle conversion of oxaloacetate to malate and fumarate where the position of the
hyperpolarized signal is scrambled due to molecular symmetry [37]. The aspartate
C4 signal was less intense than the aspartate C1 signal. However, we did not
observe oxaloacetate, malate or fumarate in any of our experiments, and therefore it
was not possible to distinguish between this scrambling and possible direct
carboxylation of pyruvate by hyperpolarized CO2
*. We further observed two
unknown peaks that were not present as impurities in the pyruvate preparation. The
one at 170.7 ppm is consistent with asparagine whilst the identity of the peak at
174.2 ppm remains to be determined.
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The aspartate C1 and C4 peaks which we observed have previously been
described in liver metabolism, which typically exhibits a greater degree of
anaplerosis than in the heart [37]. However, anaplerotic reactions are also essential
to maintain TCA cycle intermediate levels constant in the heart, and we observe
them here using DNP NMR for the first time. To date, anaplerosis has only been
studied using 13C-isotopomer analysis by MR [38–40], but no real-time estimation
of this important metabolic pathway has been carried out. Moreno et al. [38], used
isotopomer analysis of heart homogenates (from hearts similarly perfused with 3
and 6 mM pyruvate), demonstrating that 80 % of acetyl CoA arose from pyruvate
metabolism, whilst only 8–10 % was attributed to anaplerosis. Using the relative
amplitude of the aspartate C1 signal and the HCO3
- signal, we estimate PC and
PDH activity to be approximately 7 % and therefore in good agreement.
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Fig. 6 Time courses of the pyruvate, lactate and bicarbonate signals, estimated with AMARES from the
two experiments shown in Fig. 5. For experiment 1 data from the region of high lactate production
(a) and the region of high bicarbonate production (b) indicated by arrow 1 and 2 in Fig. 5c was extracted.
For experiment 2 mean data of the whole myocardium is shown. The solid lines show a fit of the data
using a bi-exponential equation for interpolation and display purposes only. d–f AMARES fitted spectra
and fit residual at the time point indicated by the dashed lines in a–c. d Average spectrum of nine voxels
in the region of high lactate production of experiment 1. e Average spectrum of 15 voxels in the region of
high bicarbonate production of experiment 1. f Average spectrum of all voxels in myocardium of
experiment 2. Bottom shows stacked plots of the spectra of the time series estimated with AMARES from
the two regions of interest in experiment 1 (g, h) and the whole myocardium in experiment 2 (i). For
better visualization without baseline distortions due to the linear phase of the spectra, absolute values are
shown
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Hyperpolarized tracers, such as [1-13C] pyruvate, may therefore be a useful tool for
real-time investigation of anaplerotic metabolism in the perfused rat heart ex vivo
with the potential to also be studied in vivo.
In the present work, fast spectroscopic imaging was implemented to dynamically
image perfusion with pyruvate and to follow its conversion to lactate and
bicarbonate in the isolated perfused heart. The early upslope of the bicarbonate
signal in experiment 1 shown in Figs. 5a and 6b compared with the pyruvate signal
is a visual effect due to the down scaling of the pyruvate signals. In fact, the upslope
of the pyruvate signals is earlier than that of the bicarbonate signals. In experiment 1
the bicarbonate signal reaches its maximum point about 5 s earlier in region 2
(between t = 10 s and t = 15 s) than with region 1 (between t = 15 and 25 s). The
image series and the spectra of experiment 1 presented in Figs. 5 and 6 show a
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Fig. 7 Schematic representation of pyruvate metabolism with the metabolites observed using non-
selective spectroscopy shown in red. We observe conversion of hyperpolarized [1-13C] pyruvate to
lactate, alanine, bicarbonate, CO2 and aspartate under the action of the enzymes lactate dehydrogenase
(LDH), alanine transaminase (ALT), pyruvate dehydrogenase (PDH), pyruvate carboxylase (PC) and
transamination of oxaloacetate to aspartate. The outer box corresponds to the plasma membrane whilst the
inner box is the mitochondrial membrane. From our experiments we are not able to distinguish between
pyruvate carboxylation via hyperpolarized CO2
* or symmetrization of oxaloacetate via conversion to
fumarate
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heterogeneous distribution of lactate and bicarbonate within the myocardium,
indicated by the two regions in Fig. 5c. In contrast, the imaging series of experiment
2 display a more homogeneous distribution of metabolites. One may note also in
this second experiment pyruvate signal arising within the left ventricle, suggesting
partial opening of the aortic valve in this experiment. These regional differences that
we observe are most likely due to regional variations in pyruvate perfusion and its
subsequent metabolism. Thus, regional differences in the magnitude of pyruvate
signal provide some insight into tissue perfusion, while regional differences in
metabolic fate provide insight into the degree of metabolic derangement that a
particular region may be experiencing due, for example, to ischaemia. Further
investigation of these effects in well-controlled models of ischemia or metabolic
perturbations is therefore needed. The heterogeneities in myocardial metabolism
that we observe cannot be detected using non-selective spectroscopy (which
averages these signals over the entire volume) and are a significant advantage of this
approach.
There are currently some limitations in our methodology for both the non-
selective spectroscopy and the spectroscopic imaging experiments. Even though all
our experiments were performed following a standard protocol, some variability in
the intensity of the metabolite peaks (Fig. 4a) was detected. Our experiments were
carried out without monitoring cardiac function, meaning that we were unable to
assess the consistency of our heart perfusion protocol after it is inserted into the
spectrometer. A lack of ECG triggering leads to image blurring along the phase
encoding direction (left, right), due to residual motion as seen in the 13C images in
Fig. 5a and b. In future experiments, the primary cardiac parameters (e.g., coronary
flow, left ventricular developed pressure and heart rate) will be detected using a
balloon inserted in the left ventricle connected to a pressure transducer. Moreover,
heart rate (and thus energy demand) will be maintained constant using an MR-
compatible pacing system, which is currently under construction. This system can
also be employed to trigger image acquisition and minimize motion-related image
blurring.
Cardiac metabolism is very sensitive to changes in substrate availability. The
choice of the composition of the Krebs–Henseleit buffer is crucial to obtain
physiologically relevant results [41]. In these experiments, the buffer contained
glucose but not fatty acids, which has been previously shown to greatly affect the
conversion of pyruvate, for example in the presence of octanoate [17]. However,
physiological long-chain fatty acids bound to albumin confound hyperpolarized
13C-MR measurements due to a significant shortening of T1 [38]. Furthermore, in
our experiments the concentration of pyruvate required to give sufficient signal-to-
noise is more than ten times higher than physiological concentrations of pyruvate in
blood [38], thus influencing substrate utilization in the heart. Further investigations
are needed to understand the impact of this upon substrate selection in our isolated
heart model.
Our imaging experiments are currently limited by sensitivity and therefore also
by temporal resolution. Advanced methods to optimize excitation angles for
pyruvate, lactate and bicarbonate independently using spatial spectral pulses in
combination with EPSI [42] or single-shot EPI (echo planar imaging) [28] readout
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could be used in future work to overcome these limitations. Additionally, partial
k-space undersampling techniques exploiting spatiotemporal correlations such as k-t
PCA [43] could be used to minimize the number of signal excitations and thus
further accelerate image acquisition.
5 Conclusion
We have implemented protocols for real-time metabolic studies in the perfused rat
heart employing both non-selective 13C MR spectroscopy and slice-selective
spectroscopic imaging for localized measurements. In agreement with previous
studies [17, 18], we have shown that it is feasible to detect the conversion of
hyperpolarized [1-13C] pyruvate to lactate, alanine, HCO3
- and CO2 using non
selective spectroscopy experiments. We have also demonstrated the conversion of
hyperpolarized [1-13C] pyruvate to aspartate C1 and C4 which we attribute to
anaplerotic metabolism. Information on the spatial distribution of hyperpolarized
pyruvate, lactate and bicarbonate was obtained using slice-selective spectroscopic
imaging employing an echo planar readout. Spatial distributions of the 13C
metabolite signals can be measured and heterogeneous metabolism within the
myocardium can be detected. Fast spectroscopic imaging of hyperpolarized
compounds is therefore a promising tool for the investigation of myocardial
metabolism in the isolated perfused heart model and an exciting prospect for
pharmacological studies.
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